VivoSeq
Other

Kidney

6

Pipeline Programs↗

8

Active Trials↗

8

Companies Involved↗

Kidney is an early-stage landscape with 6 programs across 8 companies. The most active players are Eli Lilly, Astellas, Takeda.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 2Astellas logo

Astellas

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalV

Vitae Pharmaceuticals, Inc.

0 programs

PreclinicalBayer logo

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSVaccine120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 82% of 11 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed22 · 58%
Recruiting6 · 16%
Terminated4 · 11%
Unknown status3 · 8%
Withdrawn1 · 3%
Active, not recruiting1 · 3%
Other1 · 3%

Clinical Trials

Trial Activity

38 trials

Kidney Sodium Content in Cardiorenal Patients
Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT04170855·50 enrolled
Mechanism of SGLT2 Inhibition in the Kidney
Recruiting·UUniversity of Michigan·Phase 4·NCT06291155·20 enrolled
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
Recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 3·NCT05430620·60 enrolled
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
Recruiting·Novartis logoNovartis·Phase 2·NCT06797518·20 enrolled
A Phase 1B Double Blinded Randomized Trial Evaluating Safety, Tolerability, and Immune Response of OSU-2131 a BZLF1 Peptide Vaccine With Stimulon™ QS-21 Solution Adjuvant in Healthy Volunteers and Patients Awaiting Solid Organ Transplantation
Recruiting·OOhio State University Comprehensive Cancer Center·Phase 1·NCT06741072·55 enrolled
Prevention of Weight Gain and Impaired Glucose Metabolism Post Kidney Transplantation: A Pilot and Feasibility Study
Recruiting·UUniversity of Kansas Medical Center·Preclinical·NCT06640179·60 enrolled
Effect of Terlipressin for Intraoperative Blood Pressure Management in Kidney Transplantation, A Double-blind Randomized Controlled Trial
Active, not recruiting·BBeijing Friendship Hospital·Preclinical·NCT06855758·150 enrolled
SGL-TX-PTDM: SGLT2i Effect on PTDM Development and Kidney Allograft Function in Kidney Transplant Recipients: A Randomized, Doubleblind, Placebo Controlled, National Multicenter Trial
Not yet recruiting·OOdense University Hospital·Phase 2·NCT07682350·184 enrolled
A Study About How ASP5354 Affects the Body in Healthy Adults and in Adults Whose Kidneys do Not Work Well
Completed·Astellas logoAstellas·Phase 1·NCT05495581·28 enrolled
A Study of Mobocertinib Capsules in People With Severe Kidney Problems and People With Healthy Kidneys
Completed·Takeda logoTakeda·Phase 1·NCT04056455·26 enrolled
Direct Renin Inhibition and the Kidney
Completed·VVitae Pharmaceuticals, Inc.·Phase 1·NCT01217736·22 enrolled
Rapamycin Versus Mycophenolate Mofetil in Kidney-Pancreas Recipients
Completed·UUniversity of Miami·Phase 2·NCT00533442·170 enrolled
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
Completed·UUniversity of Minnesota·Phase 2·NCT01329185·17 enrolled
Kidney Damage in Patients With Normal eGFR
Completed·BBracco Diagnostics, Inc·Phase 4·NCT01137786·49 enrolled
A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally
Completed·Bayer logoBayer·Phase 1·NCT05071729·31 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)